<DOC>
	<DOC>NCT00337922</DOC>
	<brief_summary>This study was designed to explore the drug levels in the blood in Japanese HIV-infected patients taking EPZICOM tablet at least for 2 weeks prior to administration of the study drug. Pharmacokinetics after administration of EPZICOM tablet will be investigated in a total of 8 subjects.</brief_summary>
	<brief_title>Pharmacokinetic Study Of EPZICOM Tablet</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criteria: A Japanese HIVinfected patient who continues to use one EPZICOM tablet in the morning (00:00 to 12:00) at least for 2 weeks prior to administration of the study drug. A patient who agrees to abstain from alcohol from 48 hours prior to administration of the study drug until completion of blood sampling for pharmacokinetic analysis. Exclusion criteria: A patient developing AIDS (Patients who developed AIDS in the past but have no symptoms or findings that may serve as indicators at screening may be eligible for the study.) A patient with a history of hypersensitivity to the study drug and the ingredients (lamivudine, abacavir sulfate) of the study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>EPZICOM</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Abacavir</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
</DOC>